Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
20/05/2024 13:59
May 20 (Reuters) - Kiromic Biopharma Inc KRBP.PK :
* KIROMIC BIOPHARMA ADDS UPMC AS FOURTH DELTACEL-01 CLINICAL
TRIAL
SITE
Source text for Eikon: ID:nBw5tDNmla
Further company coverage: KRBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site